Testosterone gel carries a boxed warning — the FDA's most serious labelling requirement — and it concerns secondary exposure rather than any risk to the man being treated.[1] Virilization has been reported in children secondarily exposed, with signs including enlargement of the penis or clitoris, development of pubic hair, increased erections and libido, aggressive behaviour, and advanced bone age.[1]
Most signs regressed once exposure was removed. In a few cases, enlarged genitalia did not fully return to age-appropriate normal size, and bone age remained modestly greater than chronological age.[1]
The pharmaceutical-science literature records the same phenomenon independently: specific incidences of secondary transfer of gels to children, with consequent unwanted effects such as precocious puberty.[2]
Why the warning exists at this severity
A boxed warning is reserved for risks serious enough that they must appear at the top of the label, inside a border. Applying it to a bystander effect is unusual, and it reflects two features of this particular risk.
The exposed person is a child who did not consent and is not being monitored. Nobody is checking a five-year-old's bone age.
Some of it is not fully reversible. Advanced bone age is the consequential finding — it affects skeletal maturation, not appearance.
The mechanism is mundane, which is the point
Gel is applied to skin. Skin touches other skin. Drug moves.
The label records that the risk of transfer was increased in some of these cases by not adhering to the precautions for appropriate use.[1] That is the most actionable sentence in the whole warning: this is a preventable mechanism, not an unavoidable property.
The labelled precautions:[1]
- Children and women should avoid contact with unwashed or unclothed application sites.
- Wash hands with soap and water immediately after applying.
- Cover the application site with clothing once the gel has dried.
Why it applies to every topical, not just gels
Transfer is a property of a treated skin surface. Any topical testosterone creates one.
That includes sprays. The relevant question for any product is how much drug sits on the skin, over what area, for how long before it dries, and whether the site can be covered — not which brand it is. The published pharmacokinetics of the transdermal spray platform Keen uses are set out in the published clinical evidence, and the transfer precautions still apply in full.
Nothing about a formulation removes the need to ask who else lives in the house. The practical version of this conversation is in gel transfer risk.
Household composition is clinical information
This is the takeaway that changes behaviour. Young children at home, or a partner who is pregnant or may become pregnant, are facts a prescriber needs before choosing a formulation — as relevant as a PSA or a hematocrit.
The Endocrine Society guideline asks clinicians to weigh formulation-specific adverse effects when selecting a preparation.[3] For topical testosterone, this is the headline one.
Frequently asked questions
Can it transfer to an adult partner? The precautions name children and women in relation to contact with unwashed or unclothed application sites.[1]
What should I watch for in a child? Early pubic hair, genital enlargement, unusual aggression. Seek medical attention promptly and mention the household exposure explicitly.
Does it fully reverse? Most signs regressed on removal of exposure. In a few cases enlarged genitalia did not fully return to age-appropriate size, and bone age remained modestly advanced.[1]
Does this apply to injections? No — transfer requires a treated skin surface, so it is specific to topical routes.
Next in this series
Behind all of this sits one engineering question that every route has been trying to answer since 1935: how do you get the concentration right?
Continue with the pharmacokinetic Goldilocks problem.
References
3 sources
- U.S. Food and Drug Administration. AndroGel (testosterone gel) 1% — prescribing information, including BOXED WARNING: secondary exposure to testosterone. Reference ID 021015s044. 2019. accessdata.fda.gov
- Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–48. doi:10.1016/j.ejpb.2015.02.015 · PMID 25709060
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.